-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the beginning of 2022, Renfu Medicine has ushered in good news one after another in the research and development of new drugs
.
According to reports, at the beginning of the year, Yichang Renfu Pharmaceutical's Class 2 new drug injection RF16001 received the "Clinical Trial Approval Notice" issued by the State Drug Administration.
This is the first improved complex high-end injection it has applied for.
In the field of long-acting local postoperative analgesia, there is currently no similar product on the market in China
.
Subsequently, the company's wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research and Development Center Co.
, Ltd.
(hereinafter referred to as "Renfu Research and Development Center"), and the Xinjiang Uygur Autonomous Region Uyghur Medical Research Institute, a joint research and development project Bairesi Pill also received the State Drug Administration.
Approved and issued "Drug Clinical Trial Approval Notice"
.
It is reported that Bairesi Pill is derived from the in-hospital preparations contained in the "Preparation Standards for Uyghur Medical and Medical Institutions in Xinjiang Uygur Autonomous Region".
It is applied for clinical trials in accordance with the requirements of Class 1.
1 innovative traditional Chinese medicines in the registration classification of traditional Chinese medicines, and is intended to be used for the treatment of stable vitiligo
.
In addition to the above drugs, the Phase III clinical trials of recombinant plasmid-hepatocyte growth factor injection, a high-profile class 1 biopharmaceutical drug, are also progressing normally
.
The industry believes that if the above drugs can be successfully launched, Renfu Medicine is expected to win Category 1 new drugs in the three major fields of chemical medicine, traditional Chinese medicine and biological medicine
.
In fact, in the past two years, Renfu Medicine has been approved for two new Class 1 chemical drugs
.
In July 2020, Renfu Medicine's remimazolam besylate for injection was approved for marketing, breaking the situation that no innovative drugs have been launched in the field of sedative drugs widely used at home and abroad in the past 30 years, and it is also the first chemical drug in Hubei Province.
Class 1 new drug; and in May 2021, Renfu Medicine once again "captured" a new class 1 chemical drug, fospropofol disodium for injection
.
On the whole, the analysis believes that Renfu Medicine's continuous breakthroughs in research and development in recent years are mainly due to its insistence on independent research and development innovation and continuous increase in research and development investment
.
In recent years, Renfu Medicine has continuously increased its R&D investment.
In 2018, the R&D investment was 480 million yuan, an increase of 21.
49% over the previous year.
In 2019, the R&D investment was 590 million yuan, an increase of 22.
11% over the previous year.
In 2020, the R&D investment reached 765 million yuan.
100 million yuan, an increase of 29.
4% over the previous year
.
In 2021, R&D investment will continue to increase
.
The R&D investment has increased by more than 20% every year in a row, which fully reflects the strategic goal of Renfu Pharmaceutical to be an innovative pharmaceutical company
.
It is worth mentioning that the continuous increase in R&D investment has also begun to bring rich fruits to Renfu Medicine
.
The data shows that from 2017 to December 5, 2021, Renfu Medicine has approved 16 new products, 2 class 1 new drugs, 3 first generic + first over-evaluated products, and 1 first-in-class product is concentrated in the field of nervous system drugs.
The first imitation + review product is a cardiovascular system drug
.
In addition, Renfu Medicine has more than 200 products under development, and nearly 20 Class 1 new drugs under development.
.
.
In general, Renfu Medicine has established its own advantages in many pharmaceutical segments, and Competitiveness is increasing
.
Owning innovative drugs independently developed is the key to the sustainable development of an enterprise.
In the future, with the continuous launch of innovative drugs, the industry generally believes that Renfu Medicine will embark on a higher-quality development path
.
.
According to reports, at the beginning of the year, Yichang Renfu Pharmaceutical's Class 2 new drug injection RF16001 received the "Clinical Trial Approval Notice" issued by the State Drug Administration.
This is the first improved complex high-end injection it has applied for.
In the field of long-acting local postoperative analgesia, there is currently no similar product on the market in China
.
Subsequently, the company's wholly-owned subsidiary, Wuhan Renfu Innovative Drug Research and Development Center Co.
, Ltd.
(hereinafter referred to as "Renfu Research and Development Center"), and the Xinjiang Uygur Autonomous Region Uyghur Medical Research Institute, a joint research and development project Bairesi Pill also received the State Drug Administration.
Approved and issued "Drug Clinical Trial Approval Notice"
.
It is reported that Bairesi Pill is derived from the in-hospital preparations contained in the "Preparation Standards for Uyghur Medical and Medical Institutions in Xinjiang Uygur Autonomous Region".
It is applied for clinical trials in accordance with the requirements of Class 1.
1 innovative traditional Chinese medicines in the registration classification of traditional Chinese medicines, and is intended to be used for the treatment of stable vitiligo
.
In addition to the above drugs, the Phase III clinical trials of recombinant plasmid-hepatocyte growth factor injection, a high-profile class 1 biopharmaceutical drug, are also progressing normally
.
The industry believes that if the above drugs can be successfully launched, Renfu Medicine is expected to win Category 1 new drugs in the three major fields of chemical medicine, traditional Chinese medicine and biological medicine
.
In fact, in the past two years, Renfu Medicine has been approved for two new Class 1 chemical drugs
.
In July 2020, Renfu Medicine's remimazolam besylate for injection was approved for marketing, breaking the situation that no innovative drugs have been launched in the field of sedative drugs widely used at home and abroad in the past 30 years, and it is also the first chemical drug in Hubei Province.
Class 1 new drug; and in May 2021, Renfu Medicine once again "captured" a new class 1 chemical drug, fospropofol disodium for injection
.
On the whole, the analysis believes that Renfu Medicine's continuous breakthroughs in research and development in recent years are mainly due to its insistence on independent research and development innovation and continuous increase in research and development investment
.
In recent years, Renfu Medicine has continuously increased its R&D investment.
In 2018, the R&D investment was 480 million yuan, an increase of 21.
49% over the previous year.
In 2019, the R&D investment was 590 million yuan, an increase of 22.
11% over the previous year.
In 2020, the R&D investment reached 765 million yuan.
100 million yuan, an increase of 29.
4% over the previous year
.
In 2021, R&D investment will continue to increase
.
The R&D investment has increased by more than 20% every year in a row, which fully reflects the strategic goal of Renfu Pharmaceutical to be an innovative pharmaceutical company
.
It is worth mentioning that the continuous increase in R&D investment has also begun to bring rich fruits to Renfu Medicine
.
The data shows that from 2017 to December 5, 2021, Renfu Medicine has approved 16 new products, 2 class 1 new drugs, 3 first generic + first over-evaluated products, and 1 first-in-class product is concentrated in the field of nervous system drugs.
The first imitation + review product is a cardiovascular system drug
.
In addition, Renfu Medicine has more than 200 products under development, and nearly 20 Class 1 new drugs under development.
.
.
In general, Renfu Medicine has established its own advantages in many pharmaceutical segments, and Competitiveness is increasing
.
Owning innovative drugs independently developed is the key to the sustainable development of an enterprise.
In the future, with the continuous launch of innovative drugs, the industry generally believes that Renfu Medicine will embark on a higher-quality development path
.
